Current Challenges in Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1 SUPPL., 2010, Pages

  Socie, Gerard ^a,b,c   Ritz, Jerome ^d   Martin, Paul J ^e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Chronic GvHD; Diagnostic criteria; Pathophysiology; Treatment

Indexed keywords

AZATHIOPRINE; B CELL ACTIVATING FACTOR; CD27 ANTIGEN; CYCLOSPORIN; GLUCOCORTICOID; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HY ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THALIDOMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG MEGADOSE; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HYPERBILIRUBINEMIA; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOCYTE SUBPOPULATION; MORTALITY; RECOMMENDED DRUG DOSE; REGULATORY T LYMPHOCYTE; SYSTEMIC THERAPY; T CELL DEPLETION; T LYMPHOCYTE; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICS; UNITED STATES;

GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTES; NATIONAL INSTITUTES OF HEALTH (U.S.); RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 77953057590     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.10.013     Document Type: Article

References (27)

1. Randolph S.S., Gooley T.A., Warren E.H., et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004, 103:347-352.
2. Zorn E., Miklos D.B., Floyd B.H., et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004, 199:1133-1142.
3. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004, 103:353-359.
4. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
5. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
6. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
7. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
8. Kharfan-Dabaja M.A., Mhaskar A.R., Djulbegovic B., et al. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009, 15:1005-1013.
9. Zorn E., Kim H.T., Lee S.J., et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005, 106:2903-2911.
10. Zorn E., Nelson E.A., Mohseni M., et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571-1579.
11. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after non myeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
12. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
13. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
14. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
15. Jagasia M., Giglia J., Chinratanalab W., et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007, 13:1207-1215.
16. Arora M., Nagaraj S., Witte J., et al. New classification of chronic graft versus host disease: added clarity from the consensus diagnoses. Bone Marrow Transplantation 2009, 43:149-153.
17. Cho B.-S., Min C.-K., Eom K.-S., et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009, 23:78-84.
18. Vigorito A.C., Campregher P.V., Storer B.E., et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009, 114:702-708.
19. Martin P.J., Carpenter P.A., Sanders J.E., et al. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol 2004, 79:221-228.
20. Sullivan K.M., Witherspoon R.P., Storb R., et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988, 72:546-554.
21. Koc S., Leisenring W., Flowers M.E.D., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002, 100:48-51.
22. Koc S., Leisenring W., Flowers M.E.D., et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000, 96:3995-3996.
23. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001, 7:265-273.
24. Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009, 113:5074-5082.
25. Lee S.J., Cook E.F., Soiffer R., Antin J.H. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:444-452.
26. Pavletic S., Martin P., Lee S.J., Mitchell S., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006, 12:252-266.
27. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006, 12:491-505.